BioCentury
ARTICLE | Company News

Mucosis, J&J deal

October 15, 2012 7:00 AM UTC

Mucosis granted Crucell N.V. rights to use Mimopath technology to develop vaccines against infectious diseases. The technology is based on the Lactococcus lactis bacteria, which Mucosis formulates in...